Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)

P. Knoebl*, P. Marco, F. Baudo, P. Collins, A. Huth-Kuhne, L. Nemes, F. Pellegrini, L. Tengborn, H. Levesque, G. Aspoek, M. Heistinger, P. Knobl, A Makipernaa, H. Andre, A. Aouba, Sylvia Bellucci, P. Beurrier, J.Y. Borg, L. Darnige, J. DevignesR. D'Oiron, P. Gautier, V. Gay, S. Girault, Y. Gruel, V. Guerin, N. Hezard, M. Khellaf, M. Koenig, H. Levesque, F. Lifermann, R. Marlu, Jacques Ninet, J. Peynet, T. Quemeneur, C. Rothschild, N. Schleinitz, M. Sigaud, S. Trouillier, S. Voisin, A. Giebl, K Holstein, A. Huth-Kuhne, R.M. Loreth, U. Steigerwald, A. Tiede, G. Theodossiades, P. Kamphuisen, P.W. van der Linden, J. van der Meer, Each 2 Registry Contributors

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

344 Citations (Scopus)


Background: Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies against coagulation factor VIII and characterized by spontaneous hemorrhage in patients with no previous family or personal history of bleeding. Although data on several AHA cohorts have been collected, limited information is available on the optimal management of AHA. Objectives: The European Acquired Hemophilia Registry (EACH2) was established to generate a prospective, large-scale, pan-European database on demographics, diagnosis, underlying disorders, bleeding characteristics, treatment and outcome of AHA patients. Results: Five hundred and one (266 male, 235 female) patients from 117 centers and 13 European countries were included in the registry between 2003 and 2008. In 467 cases, hemostasis investigations and AHA diagnosis were triggered by a bleeding event. At diagnosis, patients were a median of 73.9 years. AHA was idiopathic in 51.9%; malignancy or autoimmune diseases were associated with 11.8% and 11.6% of cases. Fifty-seven per cent of the non-pregnancy-related cases were male. Four hundred and seventy-four bleeding episodes were reported at presentation, and hemostatic therapy initiated in 70.5% of patients. Delayed diagnosis significantly impacted treatment initiation in 33.5%. Four hundred and seventy-seven patients underwent immunosuppression, and 72.6% achieved complete remission. Conclusions: Representing the largest collection of consecutive AHA cases to date, EACH2 facilitates the analysis of a variety of open questions in AHA.

Original languageEnglish
Pages (from-to)622-631
Number of pages10
JournalJournal of Thrombosis and Haemostasis
Issue number4
Publication statusPublished - Apr-2012


  • acquired hemophilia
  • demographics
  • diagnosis
  • outcome
  • registry
  • treatment

Cite this